Amendment to RFA-HD-05-019 Pelvic Floor Disorders Network

Notice Number: NOT-HD-06-001

Key Dates
Release Date: December 2, 2005

Issued by
National Institute of Child Health and Human Development (NICHD), (http://www.nichd.nih.gov/)

This Notice is to inform the scientific community of amendments to RFA-HD-05-019, Pelvic Floor Disorders Network originally issue on August 17, 2005 (http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-05-019.html). Specifically, this Notice:

  • Increases the allowable costs for clinical sites.
  • Clarifies the qualifications for the Principal Investigator and clinical investigators.

All other requirements outlined in the RFA remain unchanged.

Allowable Costs for Clinical Sites

The earlier guidance stated that: An applicant for a Clinical Site may request a project period for up to 5 years and a budget for direct costs associated with base costs up to $125,000 per year. This amount is changed from $125,000 to $175,000 (direct costs).

This change affects the language in the Executive Summary (3 rd bullet); the section on Funds Available (Section II.2. Award Information, Funds Available); and the 5th paragraph under Budget Preparation: Clinical Site Applicants in the Other Submission Requirements section of RFA-HD-05-019 (Section IV.6. Application and Submission Information, Other Submission Requirements, Clinical Site Applications, Budget Preparation: Clinical Site Applicants).

Qualifications for Principal Investigator and Clinical Investigators

The earlier guidance stated that: The Principal Investigator for a Clinical Site should be a practicing clinical urogynecologist in the field of female pelvic floor disorders who is able to make a substantive long-term commitment of effort to Network responsibilities.

This language is modified, as follows: The Principal Investigator should be able to make a substantive long-term commitment of effort to Network responsibilities. The clinical investigators at each Clinical Site must include a urogynecologist and a urologist with demonstrated training and experience in the diagnosis and treatment of pelvic floor disorders in women. It is expected that either a urologist or a urogynecologist will serve as the Principal Investigator for a Clinical Site.

This change affects the language in the Eligible Individuals section (Section III.1.B. Eligibility Information, Eligible Applicants, Eligible Individuals); the 2 nd bullet under the Minimum Requirements: Clinical Site in the Other Submission Requirements section (Section IV.6. Application and Submission Information, Other Submission Requirements, Clinical Site Applications, Minimum Requirements: Clinical Site); and the 1 st paragraph under Clinician-Investigators in Female Pelvic Floor Disorders: Clinical Site in the Other Submission Requirements section (Section IV.6. Application and Submission Information, Other Submission Requirements, Clinical Site Applications, Clinician-Investigators in Female Pelvic Floor Disorders: Clinical Site)

Inquiries

For further information, contact:

Anne M. Weber, M.D., M.S.
Contraception and Reproductive Health Branch
National Institute of Child Health and Human Development
6100 Executive Boulevard , Room 8B-13C, MSC 7510
Bethesda , MD 20892-7510
(Rockville , MD 20852 for express/courier service, non-US Postal Service)
Telephone: 301-496-4924
FAX: 301-480-1972
Email: webera@mail.nih.gov